Piercarlo Sarzi-Puttini to Tumor Necrosis Factor-alpha
This is a "connection" page, showing publications Piercarlo Sarzi-Puttini has written about Tumor Necrosis Factor-alpha.
Connection Strength
1.061
-
The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. Rheumatology (Oxford). 2018 10 01; 57(57 Suppl 7):vii11-vii22.
Score: 0.354
-
TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same? Autoimmun Rev. 2018 Jan; 17(1):24-28.
Score: 0.333
-
Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. Clin Exp Rheumatol. 2019 Jul-Aug; 37(4):649-655.
Score: 0.091
-
Ankylosing Spondylitis Treatment after First Anti-TNF Drug Failure. Isr Med Assoc J. 2018 Feb; 20(2):119-122.
Score: 0.085
-
Anti-tumour necrosis factor-a antibodies and B cell homeostasis in human inflammatory bowel diseases. Int Immunopharmacol. 2018 Jan; 54:329-335.
Score: 0.084
-
Potential target of infliximab in autoimmune and inflammatory diseases. Autoimmun Rev. 2007 Sep; 6(8):529-36.
Score: 0.040
-
Potential off-label use of infliximab in autoimmune and non-autoimmune diseases: a review. Autoimmun Rev. 2005 Mar; 4(3):144-52.
Score: 0.035
-
Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: results of an Italian observational study. Clin Exp Rheumatol. 2017 Nov-Dec; 35(6):919-928.
Score: 0.020
-
Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. Clin Rheumatol. 2017 Apr; 36(4):753-761.
Score: 0.020